VC Roundup: Magenta Raises $48.5m To Improve Stem Cell Transplants

The Atlas and Third Rock-backed startup Magenta raised a $48.5m Series A round to develop drugs that improve three key steps in the stem cell transplant process. Turnstone, Glycomine and Syntimmune also brought in a combined $61.4m new funding during the first half of November.

trading

Magenta Therapeutics raised $48.5m in Series A venture capital to develop therapeutics that may improve hematopoietic stem cell transplants, increase curative outcomes and induce remission for patients with hematological malignancies, genetic bloods disorders and autoimmune diseases.

A group of VC investors led by Atlas Venture and Third Rock Ventures LLC put their money behind an ambitious...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip